NasdaqGM:TNGX
NasdaqGM:TNGXBiotechs

How Does Tango Therapeutics’ (TNGX) New Equity Move Shape Its Funding Strategy?

Tango Therapeutics recently filed a US$100 million follow-on equity offering and multiple shelf registrations, including the ability to issue common stock, preferred stock, debt securities, warrants, and units. This move signals the company's focus on boosting capital flexibility, which often draws investor attention due to its impact on future funding and potential share dilution. We'll explore how Tango Therapeutics' capital-raising efforts form a key part of its investment narrative as a...
NYSE:HI
NYSE:HIMachinery

How Investors May Respond To Hillenbrand (HI) Achieving Profit Growth Despite Lower Sales

Hillenbrand reported its fourth quarter and full-year earnings for the period ended September 30, 2025, revealing fourth quarter sales of US$652.1 million and a quarterly net income of US$75.7 million, compared to US$837.6 million in sales and US$14.6 million in net income a year ago. Despite a decline in annual sales, the company's transition from a net loss to net income signals significant operational improvements over the past year. We'll explore how the sharp turnaround in net income...